Daridorexant: Independent Evidence on Insomnia, Side Effects & Withdrawal
Daridorexant (Quviviq) gives small gains over placebo for chronic insomnia with no withdrawal in trials. NICE backs it after CBTi; key trials were Idorsia-funded.
Evidence-graded research on sleep and insomnia — melatonin, magnesium and other sleep supplements assessed by the real strength of the primary evidence.
Daridorexant (Quviviq) gives small gains over placebo for chronic insomnia with no withdrawal in trials. NICE backs it after CBTi; key trials were Idorsia-funded.
Excessive daytime sleepiness & cataplexy — evidence-based treatments are prescription drugs; no supplement has adequate evidence. Independent human-trial evidence, funding traced.
Funding correction — 30 September 2026. The methods of Chandrasekhar et al. (2012) and Salve et al. (2019) disclose manufacturer-supplied ashwagandha extracts. Their financial-funding declarations do not establish independence from in-kind support. We corrected both trial labels and related summaries. An unfunded review is not proof that its pooled trials are independent. Under a strict … Read more
Key takeaways Melatonin is the only sleep supplement with strong evidence — but specifically for jet lag and circadian phase shift, not chronic insomnia (Cochrane review). A JAMA analysis found melatonin gummies’ actual content varied widely from label claims, and some products contained undisclosed CBD — a quality problem, not just an efficacy one. Magnesium … Read more
Key takeaways CBT-I (cognitive behavioral therapy for insomnia) is the guideline-recommended first-line treatment for chronic insomnia — not medication or sleep hygiene alone (ACP guideline; AASM behavioral guideline). A meta-analysis of 20 RCTs (1,162 participants) found multimodal CBT-I cut sleep-onset latency by ~19 minutes and wake-after-sleep-onset by ~26 minutes (Annals of Internal Medicine). Sleep hygiene … Read more
Key takeaways Best-supported use: pairing 100–200 mg L-theanine with caffeine (50–100 mg) to reduce jitter and improve sustained attention on cognitive tasks — multiple RCTs and one systematic review support the combination effect (Nutritional Neuroscience, Camfield 2014). For acute situational stress and anxiety, small RCTs (200–400 mg) show reductions in self-rated stress and salivary cortisol … Read more
Key takeaways Strongest evidence: correcting low dietary intake, migraine prevention (300–600 mg daily under medical supervision), and modest blood-pressure reduction — with meta-analyses supporting a systolic drop of ~2 mmHg (Cochrane, Journal of Human Hypertension). For sleep, anxiety, muscle cramps, depression, diabetes, and bone health, evidence is mixed to weak — a systematic review found … Read more
Key takeaways Melatonin is a timing signal, not a sedative — strongest evidence is for jet lag (Cochrane: 8 of 10 trials showed benefit; 0.5–5 mg equally effective, higher doses not better) and delayed sleep-wake phase disorder. For chronic adult insomnia, AASM explicitly recommends against it — the recommendation is graded weak based on small … Read more
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.